The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
Patients who participated in the PRAISE-IR single center phase II study
Patient age at transplant: ≥ 1 year and < 66 years
HLA 8/8 MRD or MUD
Conditioning intensity: myeloablative
HLA <8/8 MRD or MUD Arm B: Standard ATG dosing CD34-selection (CIBMTR population)
Patients who participated in the PRAISE-IR study
Patients who did not sign consent for research
Patient transplanted at a center that does not meet CIBMTR data quality standards